Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Atea Pharmaceuticals IncAVIR-1.450.000.501.57-33.46%-18.75%30.05$3.28$4.124,308$3.015

Detail of Atea Pharmaceuticals Inc

 
CEO
Dr. Jean-Pierre Sommadossi Ph.D.
Employees
75
Industry
Biotechnology
Sector
Healthcare
Market cap
$255M

Company details

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals Inc
AVIR • XNGS • US
$3.015
+0.12 (4.33%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.08
Margin profit
0.00%
52 week low
$2.865
52 week high
$4.56
50-day simple moving average
$3.23
200-day simple moving average
$3.28
Percent held by insiders
9.67%
Percent held by institutions
71.00%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
AVIR +4.33%
eps change
AVIR 0.00%